View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
March 11, 2021

GSK to expand clinical trial manufacturing capacity at CGT Catapult site in UK

GlaxoSmithKline (GSK) will expand its presence at the UK Cell and Gene Therapy (CGT) Catapult’s Stevenage facility to carry out good manufacturing practice (GMP) cell processing and accelerate its cell and gene therapy pipeline for clinical trials.

GlaxoSmithKline (GSK) will expand its presence at the UK Cell and Gene Therapy (CGT) Catapult’s Stevenage facility to carry out good manufacturing practice (GMP) cell processing and accelerate its cell and gene therapy pipeline for clinical trials.

As well as boosting GSK’s investment in cell and gene therapy manufacturing in the UK for clinical trials, the agreement will bring additional expertise to the collaborators already using the CGT Catapult facility in Stevenage, the company said.

The move represents a major investment by GSK in the UK CGT ecosystem and the CGT Catapult model to accelerate the setup of advanced therapy medicinal products (ATMP) manufacturing at scale.

“The UK already has significant capabilities in cell and gene therapy, and this agreement illustrates how strategic investments by GSK can make them even stronger,” said GSK’s senior vice president of medicinal science and technology Tony Wood.

“Working more closely with CGT Catapult will help us advance our promising cell and gene therapy programmes, and bring these transformative medicines more quickly to the patients who desperately need them.”

CGT Catapult was established in 2012 as an independent centre of excellence to accelerate the development of the UK’s cell and gene therapy industry, speeding the transition from scientific research to commercialisation.

The UK has become a world leader in the development of cell and gene therapies in recent years and is home to over 90 ATMP therapy developers.

Despite the obstacles presented by Covid-19, 2020 was a big year for the UK’s GMP manufacturing sector for cell and gene therapies, seeing a 48% increase in available production space.

Last month, CGT Catapult published the 2020 ATMP clinical trials database and report, which reported 20% growth in the number of ATMP clinical trials across the UK last year. This increase included growth in late-stage cell and gene therapy clinical trials, showing a continued progression towards commercialisation, CGT Catapult said.

The report also found that the number of commercially sponsored trials have surged since 2019, with an almost 30% increase from 89 to 115 trials.

Commercial trials now make up three-quarters of the ATMP trial landscape, according to the 2020 report, with the majority being sponsored by international companies.

In response to such developments, the CGT Catapult facility in Stevenage has expanded with six additional cleanrooms, which made the new agreement with GSK possible.

CGT Catapult said the added experience brought in by GSK will support the development of new capabilities to benefit future and current collaborators looking to progress their manufacturing at the Stevenage site.

“The move by a leading pharmaceutical company like GSK to establish ATMP manufacturing capabilities at the CGT Catapult facility in Stevenage highlights the UK’s globally leading position for large and smaller organisations alike to develop, manufacture and deliver cell and gene therapies,” said Cell and Gene Therapy Catapult CEO Matthew Durdy.

“With a range of collaborators already based in the facility, we look forward to participating in the collective innovation onsite to pioneer the growth in scale of advanced therapy manufacturing.”

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena